Work

Serum antibody screening using glycan arrays

Year: 2024

Type: review

Abstract: Humans and other animals produce a diverse collection of antibodies, many of which bind to carbohydrate chains, referred to as glycans. These anti-glycan antibodies are a critical part of our immune systems' defenses. Whether induced by vaccination or natural exposure to a pathogen, anti-glycan antibodies can provide protection against infections and cancers. Alternatively, when an immune response goes awry, antibodies that recognize self-glycans can mediate autoimmune diseases. In any case, serum anti-glycan antibodies provide a rich source of information about a patient's overall health, vaccination history, and disease status. Glycan microarrays provide a high-throughput platform to rapidly interrogate serum anti-glycan antibodies and identify new biomarkers for a variety of conditions. In addition, glycan microarrays enable detailed analysis of the immune system's response to vaccines and other treatments. Herein we review applications of glycan microarray technology for serum anti-glycan antibody profiling.

Source: Chemical Society Reviews

DOI: 10.1039/d3cs00693j

Authors: Samantha Marglous, Claire E. Brown, Vered Padler-Karavani, Richard D. Cummings, Jeffrey C. Gildersleeve

Institutions: National Cancer Institute, Center for Cancer Research, Tel Aviv University, Beth Israel Deaconess Medical Center, Harvard University

Language: English

Topic: Glycosylation and Glycoproteins Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, European Research Council, National Cancer Institute, National Institute of General Medical Sciences